Market Data
Market Cap₹3,178.44 Cr.
52W High₹419.8
Current Price₹283.85
52W Low₹251.9
Down from 52W High32.4 %
Face Value₹2
Performance
ROCE14.14 %
ROE10.17 %
EPS (TTM)₹3.31
EPS Prev Qtr₹3.84
EPS Last Year₹3.87
EBITDA Qtr₹41.09 Cr.
Book Value₹146
Financial Health
Debt/Equity0.01
Debt/Profit0.12
Total Assets₹1,838.761 Cr.
Dividend Yield0.48 %
Promoter Holding43.24 %
Earning Power9.97 %
Valuation
Stock P/E19.15
Industry P/E33.81
Price to Book1.95
Price to Sales4.24
Graham Number₹220.31
Key Metrics
Face Value
₹2
About Advanced Enzyme Technologies Ltd
Healthcare · Pharmaceuticals
Advanced Enzyme Technologies Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹2. Market cap ₹3,178.44 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a low Debt to Equity ratio of 0.01, indicating strong financial stability.
- The Return on Capital Employed (ROCE) is 14.14%, showing efficient use of capital.
- The Return on Equity (ROE) is 10.53%, reflecting good profitability relative to shareholder equity.
- The company has a promoter holding of 43.24%, suggesting strong management control and alignment of interests.
Weaknesses
- The Dividend Yield is only 0.47%, which may be unattractive to income-focused investors.
- The P/E Ratio of 19.43 may indicate that the stock is relatively expensive compared to its earnings.
- The P/B Ratio of 1.98 suggests that the market values the company slightly above its book value.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 184.53 | 171.95 | 203.37 | 189.79 |
| ↳ QoQ Growth | - | -6.8% | +18.3% | -6.7% |
| Expenses | 134.55 | 132.81 | 150.33 | 148.7 |
| Operating Profit | 49.98 | 39.14 | 53.04 | 41.09 |
| OPM % | 27.09% | 22.76% | 26.08% | 21.65% |
| Other Income | 10.28 | 8.47 | 7.23 | 13.02 |
| Interest | 0.72 | 0.57 | 0.57 | 0.58 |
| Depreciation | 10.08 | 10.21 | 10.19 | 9.88 |
| EBITDA | 60.06 | 49.35 | 63.23 | 50.97 |
| EBITDA Margin % | 32.55% | 28.7% | 31.09% | 26.86% |
| Profit Before Tax | 59.54 | 58.29 | 59.8 | 53.53 |
| Tax % | 24.87% | 25.92% | 24.33% | 27.91% |
| Net Profit | 44.73 | 43.18 | 45.25 | 38.59 |
| ↳ QoQ Growth | - | -3.5% | +4.8% | -14.7% |
| EPS | 3.87 | 3.8 | 3.84 | 3.31 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 22.38 | 22.385 |
| Reserves | 1398.49 | 1609.341 |
| Borrowings | 39.35 | 20.53 |
| Other Liabilities | 161.13 | 186.51 |
| Total Liabilities | 1621.35 | 1838.761 |
| Fixed Assets | 292.94 | 692.214 |
| CWIP | 21.69 | 51.169 |
| Investments | 480.33 | 583.89 |
| Other Assets | 826.39 | 511.49 |
| Total Assets | 1621.35 | 1838.761 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 142.497 |
| Cash from Investing Activity | -89.101 |
| Cash from Financing Activity | -72.544 |
| Net Cash Flow | -19.148 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 43.07% | 43.04% | 43.26% | 43.24% |
| FIIs % | 25.41% | 25.86% | 25.49% | 26.71% |
| DIIs % | 6.41% | 5.51% | 5.41% | 4.78% |
| Public % | 16.95% | 17.44% | 17.57% | 16.94% |
| No. of Shareholders | 69,637 | 68,051 | 66,193 | 63,599 |
Major Shareholders (>1%)
- Vasant RathiPromoter and Promoter Group26.68%
- Orbimed Asia Iii Mauritius Fvci LimitedPublic Shareholding12.06%
- Nalanda India Equity Fund LimitedPublic Shareholding8.45%
- Vasant And Prabha Rathi Generation TrustPromoter and Promoter Group6.70%
As of 2026-06-30View all shareholders →